SCHEMBL15565385

SCHEMBL15565385

CC(C)(C)OC(=O)N1CCC(Nc2ccc(F)cc2F)CC1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
GPR119 Q8TDV5 3/20 0.55
MAPT P10636 2/20 0.55
NPC1 O15118 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
RAB9A P51151 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
OPRM1 P35372 1/20 0.49
DNMT3A Q9Y6K1 1/20 0.49
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.48
THRB P10828 1/20 0.47
EPHX1 P07099 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3512756 0.89 ALDH1A1 (0.55) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL13060185 0.89 ALDH1A1 (0.55) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL7057469 0.88 ALDH1A1 (0.60) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL22724870 0.88 ALDH1A1 (0.56) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL31587222 0.88 ALDH1A1 (0.56) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL25390329 0.88 USP30 (0.59) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL9900230 0.88 HDAC1 (0.48) ALDH1A1GPR119SMN1; SMN2
SCHEMBL31563542 0.87 ALDH1A1 (0.53) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL20817809 0.87 ALDH1A1 (0.58) ALDH1A1GPR119MAPTNPC1MAPK1
SCHEMBL6154531 0.86 GPR119 (0.54) ALDH1A1GPR119MAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042755-A1 GPR6 INVERSE AGONISTS MAPLIGHT THERAPEUTICS INC (US) 2026-02-12 US disclosed
EP-4568668-A2 GPR6 INVERSE AGONISTS MapLight Therapeutics, Inc. (US) 2025-06-18 EP disclosed
WO-2024036288-A2 GPR6 INVERSE AGONISTS MAPLIGHT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
US-9770452-B2 Quinoxaline derivatives as GPR6 modulators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-26 US disclosed
US-20170035775-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS ENVOY THERAPEUTICS, INC. 2017-02-09 US disclosed
US-9487526-B2 Quinoxaline derivatives as GPR6 modulators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-08 US disclosed
EP-2882722-B1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS TAKEDA PHARMACEUTICAL (JP) 2016-07-27 EP disclosed
US-20150232469-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS ENVOY THERAPEUTICS, INC. 2015-08-20 US disclosed
EP-2882722-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS Envoy Therapeutics Inc. (US) 2015-06-17 EP disclosed
WO-2014028479-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS ENVOY THERAPEUTICS, INC. (US) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232469-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS GPR6, GRM6, GPR65 ALDH1A1 1308/4885GPR119 25/4885MAPT 1911/4885
US-20260042755-A1 GPR6 INVERSE AGONISTS GPR6, GPR3, GPR4 ALDH1A1 2618/4885GPR119 11/4885MAPT 4343/4885
US-20170035775-A1 QUINOXALINE DERIVATIVES AS GPR6 MODULATORS GPR6, GRM6, GPR65 ALDH1A1 1308/4885GPR119 25/4885MAPT 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.